GlassScriptPhysician profile
Michael Kevin Dougherty
NPI 1245590264
$8,914.70
in general payments reported to CMS, 2019-2025
26 companies · $2,706 in 2025
The $2,706 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $118 · 2021: $147 · 2022: $1,306 · 2023: $1,844 · 2024: $2,206 · 2025: $2,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,640 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,640.05 |
| Education | $116.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,326.61 | 2019-2025 | Linzess, Viberzi, Creon |
| Boston Scientific Corporation | $1,292.81 | 2021-2025 | Axios, General - Polypectomy, X-Tack Endoscopic Helix Tacking System |
| Takeda Pharmaceuticals U.S.A., INC. | $705.86 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $508.03 | 2019-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $480.13 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $417.36 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $382.33 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $363.60 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $358.79 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $297.66 | 2022-2025 | Ibsrela |
| Pfizer INC. | $245.72 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $207.42 | 2019-2025 | Ocaliva |
| Celltrion USA INC. | $180.32 | 2024-2025 | Vegzelma, Zymfentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.96 | 2022-2025 | Trulance, Xifaxan, Plenvu |
| Medtronic, INC. | $146.55 | 2022-2023 | Pillcam |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $142.66 | 2023 | Erbe Apc3 |
| Madrigal Pharmaceuticals | $114.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $110.99 | 2022-2025 | Dificid, Zerbaxa |
| Nestle Healthcare Nutrition INC. | $88.58 | 2021-2023 | |
| Celgene Corporation | $88.24 | 2022-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $87.43 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $62.27 | 2025 | Iqirvo |
| Lilly USA, LLC | $56.51 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $46.97 | 2020-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $18.60 | 2022 | |
| Intra-Sana Laboratories | $14.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.